Publications by authors named "Richard A Hubner"

Claim this Profile
A
Advanced Ampullary Cancer: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.
Angela Lamarca, Paul Ross, Harpreet S Wasan, Richard A Hubner, Mairéad G McNamara

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.
Eleni Vrana, Hayley Timmins, Ashley Osborne, Rebecca Cox, Harpreet Wasan, Richard A Hubner

Future Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Richard A Hubner

Future Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Metastatic Pancreatic Cancer-Current Landscape and Future Directions.
Daniel Netto, Melissa Frizziero, Victoria Foy, Mairéad G McNamara, Alison Backen, Richard A Hubner

Curr Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer.
Shaun Alexander, Umair Aleem, Timothy Jacobs, Melissa Frizziero, Victoria Foy, Richard A Hubner

Cancers (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatostatin Receptor Imaging with [F]FET-βAG-TOCA PET/CT and [Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
Suraiya Dubash, Tara D Barwick, Kasia Kozlowski, Andrea G Rockall, Sairah Khan, Richard A Hubner

J Nucl Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.
Angela Lamarca, Lorena Ostios, Mairéad G McNamara, Carlos Garzon, Jack P Gleeson, Richard A Hubner

Cancer Treat Rev· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.
Constance d'Abrigeon, Mairéad G McNamara, Samuel Le Sourd, Angela Lamarca, Astrid Lièvre, Richard A Hubner

Br J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Richard A Hubner

Lancet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre.
Sarah Clelland, Christina L Nuttall, Helen E Stott, Joseph Cope, Natalie L Barratt, Richard A Hubner

Healthcare (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma.
Jamie M J Weaver, Richard A Hubner, Juan W Valle, Mairead G McNamara

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H Cafferty, Giovanna Petrucci, David A Cameron, Richard A Hubner

Br J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma.
Victoria Foy, Mairéad G McNamara, Juan W Valle, Angela Lamarca, Julien Edeline, Richard A Hubner

Curr Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?
Maria Passhak, Mairéad G McNamara, Richard A Hubner, Irit Ben-Aharon, Juan W Valle

Best Pract Res Clin Endocrinol Metab· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know.
Matthew D Robinson, Mairéad G McNamara, Hamish W Clouston, Paul A Sutton, Richard A Hubner

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
Mairéad G McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Richard A Hubner

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes.
Simon Gray, Octave Letissier, Constance d'Abrigeon, Dinakshi Shah, Stephen Wardell, Richard A Hubner

Cancers (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.
Reem D Mahmood, Kathryn Graham, Jack Gleeson, Richard A Hubner, Juan W Valle

Immunotherapy· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Jianming Xu, Ken Kato, Eric Raymond, Richard A Hubner, Yongqian Shu

Lancet Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment-PanDA).
Lindsay E Carnie, Dinakshi Shah, Kate Vaughan, Zainul Abedin Kapacee, Lynne McCallum, Richard A Hubner

Cancers (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.
Matthew D Robinson, Daniel Livesey, Richard A Hubner, Juan W Valle, Mairéad G McNamara

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer.
Rille Pihlak, Melissa Frizziero, Soo Yit Gustin Mak, Christina Nuttall, Angela Lamarca, Richard A Hubner

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies.
Dinakshi Shah, Zainul Abedin Kapacee, Angela Lamarca, Richard A Hubner, Juan W Valle

Expert Rev Anticancer Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary.
Alicia-Marie Conway, Georgina C Morris, Sarah Smith, Monique Vekeria, Prakash Manoharan, Richard A Hubner

Br J Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes.
Rodrigo G Taboada, Rachel P Riechelmann, Carine Mauro, Milton Barros, Richard A Hubner

Oncologist· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis